News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lux Biosciences Receives Complete Response Letter from FDA for Luveniq(TM)


8/4/2010 12:19:56 PM

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration’s Center of Drug Evaluation and Research has issued a Complete Response letter regarding the New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis.

Read at BioSpace.com

comments powered by Disqus
   
Uveitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES